Roanna Ruiz
Stock Analyst at Leerink Partners
(0.63)
# 3,763
Out of 4,784 analysts
62
Total ratings
26.32%
Success rate
-20.79%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $5 → $6 | $5.58 | +7.53% | 5 | Mar 7, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $6.74 | +167.06% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $0.57 | +75.28% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $6.70 | +198.51% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $12.49 | +116.17% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $3.02 | +330.46% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $4.93 | +183.98% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $306.97 | +7.50% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $43.19 | +34.29% | 1 | Aug 15, 2023 | |
| CORT Corcept Therapeutics | Initiates: Market Perform | $25 | $54.63 | -54.24% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $5.71 | +758.14% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $2.78 | +368.47% | 7 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $2.93 | +104.78% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $21.76 | -12.68% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $96.16 | +24.79% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $9.12 | +448.25% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3 → $2 | $0.44 | +354.34% | 6 | Oct 19, 2022 |
Xeris Biopharma Holdings
Mar 7, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $5.58
Upside: +7.53%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $6.74
Upside: +167.06%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $0.57
Upside: +75.28%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $6.70
Upside: +198.51%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $12.49
Upside: +116.17%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $3.02
Upside: +330.46%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $4.93
Upside: +183.98%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $306.97
Upside: +7.50%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $43.19
Upside: +34.29%
Corcept Therapeutics
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $54.63
Upside: -54.24%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $5.71
Upside: +758.14%
Jan 27, 2023
Maintains: Outperform
Price Target: $12 → $13
Current: $2.78
Upside: +368.47%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $2.93
Upside: +104.78%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $21.76
Upside: -12.68%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $96.16
Upside: +24.79%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $9.12
Upside: +448.25%
Oct 19, 2022
Maintains: Market Perform
Price Target: $3 → $2
Current: $0.44
Upside: +354.34%